33 Bibliografia 1. Snowden JA, Sánchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant. 2022 Aug;57(8):1217-1239 2. Passweg JR, Baldomero H, Chabannon C, Corbacioglu S, de la Camara R, Dolstra H, et al. Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020. A report from the EBMT activity survey. Bone Marrow Transplant. 2022:1–11 3. Gooptu M, Romee R, St Martin A, Arora M, Al Malki M, Antin JH, et al. HLA- haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. Blood. 2021;138:273–82 4. Sanz J, Galimard JA, Labopin M, Afanasyev B, Angelucci E, Ciceri F, et al. Post- transplant cyclophosphamide after matched sibling, unrelated and haploiden- tical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. J HematolOncol. 2020;13:46 5. Sanz J, Galimard JE, Labopin M, Afanasyev B, Sergeevich MI, Angelucci E, et al. Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT. J HematolOncol. 2021;14:84 6. Battipaglia G, Galimard JE, Labopin M, Raiola AM, Blaise D, Ruggeri A, et al. Post- transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant. 2022;57:562–71 7. Shouval R, Fein JA, Shouval A, Danylesko I, Shem-Tov N, Zlotnik M, et al. External validation and comparison of multiple prognostic scores in allogeneic hema- topoietic stem cell transplantation. Blood Adv. 2019;3:1881–90 8. McDonald GB, Sandmaier BM, Mielcarek M, Sorror M, Pergam SA, Cheng GS, et al. Survival, nonrelapse mortality, and relapse-related mortality after allo- geneic hematopoietic cell transplantation: comparing 2003-2007 versus 2013- 2017 cohorts. Ann Intern Med. 2020;172:229–39 9. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47 10. Nagler A, Savani BN, Labopin M, Polge E, Passweg J, Finke J, et al. Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis. Lancet Hae- matol. 2015;2:e384–92 11. Gilleece MH, Labopin M, Savani BN, Yakoub-Agha I, Socie G, Gedde-Dahl T, et al. Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT. Leukemia. 2020;34:87–99 12. Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11:41 13. Giebel S, Marks DI, Boissel N, Baron F, Chiaretti S, Ciceri F, et al. Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2019;54:798–80 14. Pidala J, Djulbegovic B, Anasetti C, Kharfan-Dabaja M, Kumar A. Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission. Cochrane Database Syst Rev. 2011;2011:Cd008818 15. Giebel S, Labopin M, Socie G, Beelen D, Browne P, Volin L, et al. Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102:139–49. 16. Nagler A, Labopin M, Koc Y, Angelucci E, Tischer J, Arat M, et al. Outcome of T- cell-replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2021;127:2507–14 17. Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020;395:1146–62 18. Short NJ, Kantarjian H, Jabbour E. Optimizing the treatment of acute lympho- blastic leukemia in younger and older adults: new drugs and evolving paradigms. Leukemia. 2021;35:3044–58. 19. Muffly L, Kebriaei P. Philadelphia chromosome positive acute lymphoblastic leukemia in adults: therapeutic options and dilemmas in 2020. Semin Hematol. 2020;57:137–41 20. Pavlů J, Labopin M, Niittyvuopio R, Socie G, Yakoub-Agha I, Wu D, et al. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. J Hematol Oncol. 2019;12:108 21. Stock W, Luger SM, Advani AS, Yin J, Harvey RC, Mullighan CG, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019;133:1548–59 22. Lazaryan A, Dolan M, Zhang MJ, Wang HL, Kharfan-Dabaja MA, Marks DI, et al. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia- negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. Haematologica. 2021;106:2295–6 23. Brissot E, Labopin M, Russo D, Martin S, Schmid C, Glass B, et al. Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplan- tation in second complete remission: a report from the EBMT Acute Leukemia Working Party. Bone Marrow Transplant. 2020;55:1763–72 24. Pavlů J, Labopin M, Zoellner AK, Sakellari I, Stelljes M, Finke J, et al. Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: a report from the Acute Leukemia Working Party of the EBMT. Cancer. 2017;123:1965–70 25. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisa- genlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439– 48 1. Aspetti Generali
RkJQdWJsaXNoZXIy ODUzNzk5